Pacira BioSciences, Inc. Price-FCF Ratio
The price-to-free-cash-flow (P/FCF) ratio tells you how many dollars investors pay for each dollar of cash a company generates after paying for its capital spending. It is market capitalization divided by free cash flow over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher ratio means investors are paying more for each dollar of free cash flow; a negative ratio means the company spent more cash than it generated over those quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
- Pacira BioSciences, Inc. price-fcf ratio for the quarter ending 2026-06-30 was 5.63, a 38.56% decline year-over-year.
- Pacira BioSciences, Inc. price-fcf ratio for the quarter ending 2026-03-31 was 6.69, a 7.22% decline year-over-year.
- Pacira BioSciences, Inc. price-fcf ratio for the quarter ending 2025-12-31 was 7.78, a 59.64% increase year-over-year.
- Pacira BioSciences, Inc. price-fcf ratio for the quarter ending 2025-09-30 was 8.91, a 148.40% increase year-over-year.
- Pacira BioSciences, Inc. price-fcf ratio for fiscal 2026 was 5.63.
- Pacira BioSciences, Inc. price-fcf ratio for fiscal 2025 was 7.78, a 59.64% increase from fiscal 2024.
- Pacira BioSciences, Inc. price-fcf ratio for fiscal 2024 was 4.87, a 56.65% decline from fiscal 2023.
- Pacira BioSciences, Inc. price-fcf ratio for fiscal 2023 was 11.24, a 26.96% decline from fiscal 2022.
- Available history
- 2011-06-30 to 2026-06-30
- Data captured
Historical Price-FCF Ratio
Annual Price-FCF Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |